Zelnorm has been pulled, as there is a small association with heart attacks when taking this IBS drug:
Swiss pharmaceutical maker Novartis AG will stop selling a drug to relieve constipation after it was linked to a higher chance of heart attack, stroke and worsening chest pain that can become a heart attack, federal health officials said Friday . . .
. . . Earlier this year, Novartis gave the FDA the results of 29 clinical studies of Zelnorm for treatment of a variety of gastrointestinal tract conditions. The analyses showed 13 of 11,614 patients given Zelnorm had serious and life-threatening cardiovascular side effects, while just one of the 7,031 patients given dummy pills did, the FDA and Novartis said in separate statements.







![Why modern dentists must train like pilots [PODCAST]](https://kevinmd.com/wp-content/uploads/Design-3-190x100.jpg)


![A lawyer’s essential checklist for physician side hustles [PODCAST]](https://kevinmd.com/wp-content/uploads/Design-1-190x100.jpg)
